Stocktoria
PRECIGEN, INC. PGEN
PRECIGEN, INC. (PGEN) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $9.7M at a -2588.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PGEN | PRECIGEN, INC. | 2/9 | — | — | — |
| PRTA | PROTHENA CORP PUBLIC LTD CO | 1/9 | -5.98 | — | -92.8% |
| JANX | Janux Therapeutics, Inc. | 2/9 | — | — | -5.6% |
| CBIO | CRESCENT BIOPHARMA, INC. | 4/9 | 4.59 | — | — |
| ROIV | Roivant Sciences Ltd. | 1/9 | 18.07 | — | -71.6% |
| COYA | Coya Therapeutics, Inc. | 2/9 | 5.24 | — | — |
| JAGX | Jaguar Health, Inc. | 2/9 | — | — | -1.5% |
About PRECIGEN, INC.
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
FAQ
Is PGEN financially healthy?
PRECIGEN, INC.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does PGEN pay a dividend?
No, PRECIGEN, INC. does not currently pay a dividend.
How profitable is PGEN?
In FY2025, PRECIGEN, INC. had a net margin of -2588.2% and a return on equity of -1198.6%.
What is the analyst price target for PGEN?
The average Wall-Street price target for PRECIGEN, INC. is $12.45, about 81.8% above the recent price, from 2 analysts.
Is PGEN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on PRECIGEN, INC.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.